Delivery of plant-made vaccines and therapeutics

Pelosi, Assunta; Shepherd, Robert; Walmsley, Amanda Maree

doi:10.1016/j.biotechadv.2011.07.018

Cited by 30 publications

(20 citation statements)

References 111 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Oral delivery represents one of the greatest challenges in vaccine development (Pelosi et al 2011 Mice were immunised with either VR1020 or VR1020-NbPyMSP1 19 plasmids by gene gun and gavaged with either wild type leaf powder or with NbPyMSP1 19 -containing leaf powder vaccination via the oral route is hampered by the harsh environment of the gastrointestinal tract as well as the balancing of complex processes that govern the induction of immunogenicity or immune tolerance following presentation of a protein at a mucosal surface. However, the potential advantages of oral delivery to vaccination campaigns are immeasurable in terms of compliance and vaccine coverage (Clements et al 2008).…”

Section: Discussionmentioning

confidence: 99%

Production, characterisation and immunogenicity of a plant-made Plasmodium antigen—the 19 kDa C-terminal fragment of Plasmodium yoelii merozoite surface protein 1

Chung

Wang

Webster

et al. 2011

Appl Microbiol Biotechnol

View full text Add to dashboard Cite

Development of a safe, effective and affordable malaria vaccine is central to global disease control efforts. One of the most highly regarded proteins for inclusion in an asexual blood stage subunit vaccine is the 19-kDa C-terminal fragment of merozoite surface protein 1 (MSP1(19)). As production of vaccine antigens in plants can potentially overcome cost and delivery hurdles, we set out to produce MSP1(19) in plants, characterise the protein and test its immunogenicity using a mouse model. Plasmodium yoelii MSP1(19) (PyMSP1(19)) was produced in Nicotiana benthamiana using the MagnICON® deconstructed TMV-based viral vector. PyMSP1(19) yield of at least 23% total soluble protein (TSP;3-4 mg/g Fwt) were achieved using a codon-optimised construct that was targeted to the apoplast. Freeze-dried leaf powder contained at least 20 mg PyMSP1(19) per gram dry weight and the protein retained immunogenicity in this form for more than 2 years. Characterisation studies, including SDS-PAGE, mass spectrometry and circular dichroism, indicated that the plant-expressed PyMSP1(19) was similar to its Escherichia coli- and Saccharomyces cerevisiae-expressed counterparts. Purified plant-made PyMSP1(19) induced strong immune responses following intraperitoneal immunisation, although titres were lower than those induced by an equivalent dose of purified E. coli-expressed PyMSP1(19). The reason for this is uncertain but may be due to differences in the oligomerisation profile of the vaccines. The plant-made PyMSP1(19) vaccine was also found to be orally immunogenic when delivered alone or following immunisation with a PyMSP1(19) DNA vaccine. This study adds to an increasing body of research supporting the feasibility of plants as both a factory for the production of malaria antigens, and as a safe and affordable platform for oral delivery of a temperature-stable malaria vaccine.

show abstract

Section: Discussionmentioning

confidence: 99%

Production, characterisation and immunogenicity of a plant-made Plasmodium antigen—the 19 kDa C-terminal fragment of Plasmodium yoelii merozoite surface protein 1

Chung

Wang

Webster

et al. 2011

Appl Microbiol Biotechnol

View full text Add to dashboard Cite

show abstract

“…The destructive effect of digestive processes on proteins is a significant concern for oral administration of biopharmaceuticals; this can lead to variations in the quantity and quality of therapeutic agent experienced by the body or recognised by the immune system. Nevertheless, orally administered proteins in plant material have been shown to be biologically active and efficacious in animal and human trials [33,34]. Encapsulation of the drug within the cellulosic plant cell walls affords it some degree of protection; directed aggregation of proteins in subcellular organelles and addition of adjuvants may also be used to improve protein longevity within the digestive tract [34].…”

Section: Advantages Of Using In Vitro Plant Cultures For Foreign Protmentioning

confidence: 99%

Therapeutically Important Proteins From In Vitro Plant Tissue Culture Systems

Doran¹

2013

Current Medicinal Chemistry

View full text Add to dashboard Cite

Plant cells cultured in liquid medium in bioreactors are now being used commercially to produce biopharmaceutical proteins. The emergence of in vitro plant cell culture as a production vehicle reflects the importance of key biosafety and biocontainment concerns affecting the competitiveness of alternative systems such as mammalian cell culture and agriculture. Food plant species are particularly attractive as hosts for in vitro protein production: the risk of transgene escape and food chain contamination is eliminated using containment facilities, while regulatory approval for oral delivery of drugs may be easier than if non-edible species were used. As in whole plants, proteolysis in cultured plant cells can lead to significant degradation of foreign proteins after synthesis; however, substantial progress has been made to counter the destructive effects of proteases in plant systems. Although protein secretion into the culture medium is advantageous for product recovery and purification, measures are often required to minimise extracellular protease activity and product losses due to irreversible surface adsorption. Disposable plastic bioreactors, which are being used increasingly in mammalian cell bioprocessing, are also being adopted for plant cell culture to allow rapid scale-up and generation of saleable product. This review examines a range of technical and regulatory issues affecting the choice of industrial production platform for foreign proteins, and assesses progress in the development of in vitro plant systems for biopharmaceutical production.

show abstract

“…These vaccines prevent the growth of pathological strains to a great extent. They also prevent risk of allergy and trouble of attenuated strains [26].…”

Section: A Rt I C L E I N F O Abstractmentioning

confidence: 99%

Biotechnological leap in biopharmaceuticals: Current status and challenges ahead

2016

J Coast Life Med

View full text Add to dashboard Cite

Delivery of plant-made vaccines and therapeutics

Cited by 30 publications

References 111 publications

Production, characterisation and immunogenicity of a plant-made Plasmodium antigen—the 19 kDa C-terminal fragment of Plasmodium yoelii merozoite surface protein 1

Production, characterisation and immunogenicity of a plant-made Plasmodium antigen—the 19 kDa C-terminal fragment of Plasmodium yoelii merozoite surface protein 1

Therapeutically Important Proteins From In Vitro Plant Tissue Culture Systems

Biotechnological leap in biopharmaceuticals: Current status and challenges ahead

Contact Info

Product

Resources

About